US · Healthcare · Biotechnology
EPS came in at 4.21 against a street estimate of 4.36 — a miss of 3.4%.
Analysts rate Vertex Pharmaceuticals Inc a buy (26 buy, 4 hold, 2 sell out of 32) with an average price target of $578.71.
CONFIDENT Vertex posted 12% YoY revenue growth to $3.3B, raising FY26 guidance to $13.1–13.2B. CF dominance holds; CASGEVY and JOURNAVX scaling rapidly. Pove (IgAN) BLA accepted with Nov 30 PDUFA. Crinetics acquisition adds endocrine pillar. Q2 2026 CF growth balanced US/intl; ALYFTREK uptake strong in Europe (>1 in 3 eligible in Germany, UK). FX tailwind ~170 bps. Analysts pressed CF competitive bar, JOURNAVX payer dynamics, and near-term data catalysts. Management emphasized high bar for next-gen CF (must beat <30 mmol/L achievement), PSP normalization post-physician education, and upcoming AMPLIFIED/AMPLITUDE readouts (fall 2026, early 2027). 2026-08-03…
Full summary in the app.
| Fund | Stake |
|---|---|
| Capital World Investors | 10.30% |
| BlackRock Inc | 9.51% |
| Capital Research Global Investors | 7.69% |
| Vanguard Capital Management, LLC | 6.54% |
| State Street Corp | 4.68% |
| Amvescap Plc. | 3.17% |
| JPMorgan Chase & Co | 2.57% |
| Geode Capital Management, LLC | 2.37% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 product revenue was $3,440.8 million, up from $3,076.4 million in the third quarter of 2025. • Nine-month 2026 | 2026-11-03 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $3.44 billion, up 12% from $3.0764 billion in the third quarter of 2025. • GAAP net income was $65 | 2026-11-02 |
| Board / officer change · Q4 2026 OTHER NOTABLE POINTS • Vertex Pharmaceuticals appointed Daniel Brennan to its board of directors on October 20, 2026. • The board increased from ten | 2026-10-20 |
| Board / officer change · Q3 2026 VERTEX PHARMACEUTICALS INCORPORATED - FORM 8-K SUMMARY HEADLINE NUMBERS • No financial results reported in this filing (Form 8-K is a personnel/gove | 2026-09-01 |
| Quarterly report · Q2 2026 VERTEX PHARMACEUTICALS INCORPORATED Q2 2026 10-Q SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Total revenues (6 months ended June 30, 2026): | 2026-08-04 |
| Results announced · Q3 2026 VERTEX PHARMACEUTICALS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total revenue: $3.33 billion in Q2 2026, up 12% from Q2 2025 • Full-year 2026 re | 2026-08-03 |
| Material agreement · Q3 2026 VERTEX PHARMACEUTICALS ACQUISITION OF CRINETICS PHARMACEUTICALS HEADLINE NUMBERS • Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceutical | 2026-07-07 |
| Board / officer change · Q2 2026 VERTEX PHARMACEUTICALS INCORPORATED - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • This is a corporate governance filing related to the company's ann | 2026-05-13 |
Readable in the app.
| Announcement | Date |
|---|---|
| Full-year revenue guidance raised to $13.15 billion–$13.25 billion Vertex reported strong third-quarter operating performance, but acquisition costs significantly reduced GAAP earnings. Revenue rose 12% year over year to $3.44 billion, helped by continued d | 2026-11-02 |
| Entered into agreement to acquire Crinetics Pharmaceuticals Vertex Pharmaceuticals reported strong Q2 2026 results with total revenue of $3.33 billion, up 12% year-over-year. The company raised its full-year 2026 revenue guidance to $13.1-$13.2 billi | 2026-08-03 |
| Execution of merger agreement with Parent announced On July 6, 2026, a company announced it signed a merger agreement to be acquired by a parent company. The deal is expected to bring significant benefits: the combined entity could generate o | 2026-07-07 |
| Full year 2026 revenue guidance provided; non-CF products expected to contribute $500M+ Vertex Pharmaceuticals reported strong 2025 financial results with $12.0 billion in total revenue, a 9% increase year-over-year. Fourth quarter revenue reached $3.19 billion, up 10% from the | 2026-02-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vertex Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.